全文获取类型
收费全文 | 29061篇 |
免费 | 2144篇 |
国内免费 | 1204篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 329篇 |
妇产科学 | 176篇 |
基础医学 | 2835篇 |
口腔科学 | 1259篇 |
临床医学 | 1971篇 |
内科学 | 3833篇 |
皮肤病学 | 327篇 |
神经病学 | 2674篇 |
特种医学 | 732篇 |
外国民族医学 | 6篇 |
外科学 | 2152篇 |
综合类 | 3765篇 |
现状与发展 | 2篇 |
预防医学 | 1876篇 |
眼科学 | 288篇 |
药学 | 8137篇 |
5篇 | |
中国医学 | 1352篇 |
肿瘤学 | 570篇 |
出版年
2023年 | 319篇 |
2022年 | 394篇 |
2021年 | 863篇 |
2020年 | 677篇 |
2019年 | 643篇 |
2018年 | 692篇 |
2017年 | 706篇 |
2016年 | 711篇 |
2015年 | 780篇 |
2014年 | 1482篇 |
2013年 | 1907篇 |
2012年 | 1482篇 |
2011年 | 1655篇 |
2010年 | 1482篇 |
2009年 | 1333篇 |
2008年 | 1377篇 |
2007年 | 1386篇 |
2006年 | 1298篇 |
2005年 | 1190篇 |
2004年 | 1130篇 |
2003年 | 1009篇 |
2002年 | 883篇 |
2001年 | 805篇 |
2000年 | 742篇 |
1999年 | 657篇 |
1998年 | 558篇 |
1997年 | 628篇 |
1996年 | 535篇 |
1995年 | 524篇 |
1994年 | 471篇 |
1993年 | 379篇 |
1992年 | 388篇 |
1991年 | 352篇 |
1990年 | 315篇 |
1989年 | 305篇 |
1988年 | 276篇 |
1987年 | 202篇 |
1986年 | 214篇 |
1985年 | 279篇 |
1984年 | 226篇 |
1983年 | 172篇 |
1982年 | 179篇 |
1981年 | 163篇 |
1980年 | 136篇 |
1979年 | 131篇 |
1978年 | 83篇 |
1977年 | 81篇 |
1976年 | 58篇 |
1975年 | 40篇 |
1974年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《Journal of vascular and interventional radiology : JVIR》2022,33(9):1034-1044.e29
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies. 相似文献
5.
Tobias Hüppe Sascha Kreuer Hinnerk Wulf Dennik Freitag Martin Seidel Tobias Teucke Felix Maurer Andreas Kirschbaum Tilo Koch Frank Langer Thomas Volk Carsten Feldmann 《Acta anaesthesiologica Scandinavica》2023,67(4):455-461
Background
Volatile propofol can be measured in exhaled air and correlates to plasma concentrations with a time delay. However, the effect of single-lung ventilation on exhaled propofol is unclear. Therefore, our goal was to evaluate exhaled propofol concentrations during single-lung compared to double-lung ventilation using double-lumen tubes.Methods
In a first step, we quantified adhesion of volatile propofol to the inner surface of double-lumen tubes during double- and single-lumen ventilation in vitro. In a second step, we enrolled 30 patients scheduled for lung surgery in two study centers. Anesthesia was provided with propofol and remifentanil. We utilized left-sided double-lumen tubes to separately ventilate each lung. Exhaled propofol concentrations were measured at 1-min intervals and plasma for propofol analyses was sampled every 20 min. To eliminate the influence of dosing on volatile propofol concentration, exhalation rate was normalized to plasma concentration.Results
In-vitro ventilation of double-lumen tubes resulted in increasing propofol concentrations at the distal end of the tube over time. In vitro clamping the bronchial lumen led to an even more pronounced increase (Δ AUC +62%) in propofol gas concentration over time. Normalized propofol exhalation during lung surgery was 31% higher during single-lung compared to double-lung ventilation.Conclusion
During single-lung ventilation, propofol concentration in exhaled air, in contrast to our expectations, increased by approximately one third. However, this observation might not be affected by change in perfusion-ventilation during single-lung ventilation but rather arises from reduced propofol absorption on the inner surface area of the double-lumen tube. Thus, it is only possible to utilize exhaled propofol concentration to a limited extent during single-lung ventilation.Registration of Clinical Trial
DRKS-ID DRKS00014788 ( www.drks.de ). 相似文献6.
7.
目的:探讨门脉期双源CT多个定量参数与胃腺癌病理分化程度及HER2的相关性。方法: 回顾性分析2018年7月至2019年4月间于陕西省人民医院行双源CT双能量扫描的48例经胃镜活检(21例)或手术病理证实(27例)的胃腺癌及30例正常胃的影像学资料,其中27例HER2指标明确,通过西门子第二代双源CT扫描获得静脉期双能量图像,利用syngo.via软件获得曲线斜率、门脉期碘浓度、标准化碘浓度;将患者分为胃腺癌与正常胃壁组,高、中、低分化胃腺癌组,HER2阳性组(+,++,+++)与HER2阴性组(-)。统计学方法采用Kappa一致性检验、ROC曲线法、两独立样本t检验及方差分析。结果:活检与术后病理结果具有较强的一致性(Kappa系数为0.701),两者无明显差异;胃腺癌与正常胃壁两组间能谱曲线斜率(1.35±0.24、2.19±0.71)及标准化碘浓度(0.31±0.079、0.54±0.157)均具有统计学意义(P<0.05),曲线下面积分别为0.992、0.919;低分化、中分化及高分化胃腺癌能谱曲线斜率值(3.07±0.67,2.63±0.57,2.01±0.39)组间及组内差异均具有统计学意义(P<0.05),低分化、中分化及高分化胃腺癌门脉期标准化碘浓度(0.60±0.167,0.52±0.089,0.36±0.039)组间差异具有统计学意义(P<0.05),中分化组与低分化组差异无统计学意义(P>0.05),高分化组与中、低分化组均具有统计学差异(P<0.05)。HER2阳性组与阴性组的能谱曲线斜率及标准化碘浓度值无统计学差异(P>0.05)。结论:能谱曲线斜率及门脉期标准化碘浓度值有助于对胃腺癌进行诊断并推测病理分化程度;双源CT定量参数与免疫组化指标HER2无相关性。 相似文献
8.
《药学学报(英文版)》2020,10(5):799-811
Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, rociletinib (CO-1686), a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was found to significantly improve the efficacy of ABCG2 substrate chemotherapeutic agents in the transporter-overexpressing cancer cells in vitro and in MDR tumor xenografts in nude mice, without incurring additional toxicity. Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates. Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2. However, ABCG2 expression at mRNA and protein levels was not altered in the ABCG2-overexpressing cells after treatment with rociletinib. In addition, rociletinib did not inhibit EGFR downstream signaling and phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK). Our results collectively showed that rociletinib reversed ABCG2-mediated MDR by inhibiting ABCG2 efflux function, thus increasing the cellular accumulation of the transporter substrate anticancer drugs. The findings advocated the combination use of rociletinib and other chemotherapeutic drugs in cancer patients with ABCG2-overexpressing MDR tumors. 相似文献
9.
Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) is the fourth commonest female malignancy worldwide. CESC progresses in immune-microenvironment mainly composed of infiltrating immune and stromal cells. Here, we performed an integrated analysis incorporating the expression profiles from the Cancer Genome Atlas (TCGA) database and scores of immune and stromal cells calculated by Estimation of Stromal and Immune cells in Malignant Tumours using Expression data (ESTIMATE) algorithm. A two-gene signature (CD1C and CD6 genes) was established to predict the prognosis of CESC. Based on this signature, patients were divided into the high- and low-risk groups, and this signature showed good prognostic performance according to the results of Kaplan-Meier analysis and receiver operating characteristic (ROC) analysis in train set and two validation sets. A nomogram was built for evaluating the clinical applicability of this signature. In addition, based on Tumor Immune Estimation Resource (TIMER) database, 2 hub genes showed negative correlations with tumor purity and positive correlations with infiltrating levels of immune filtrating cells. What’s more, we propose new treatment strategies for the two prognostic subtypes. Low- risk patients were found presenting with a higher level of immune checkpoint molecules and showing higher immunogenicity in immunophenoscore (IPS) analysis, which indicated a better response for immunotherapy. Meanwhile, estimated by Genomics of Drug Sensitivity in Cancer (GDSC) database, the high-risk patients showed sensitive responses to five chemotherapy drugs. Finally, 10 candidate small-molecule drugs for CESC were defined. In summary, the CD1C-CD6 signature can accurately predict the prognosis of CESC. 相似文献
10.